Study of SCY-635, Pegasys and Copegus in Hepatitis C
| Status: | Archived |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2010 |
A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection
This study will examine the effectiveness of 28 days of triple combination therapy including
SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An
additional 44 weeks of treatment with the currently approved standard of care will be
offered to all participants.
We found this trial at
4
sites
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials